NERV earnings call for the period ending March 31, 2019.
News & Analysis: Minerva Neurosciences
NERV earnings call for the period ending December 31, 2018.
These two news items were the primary reasons that Minerva's stock shed nearly a third of its value last month.
Minerva Neurosciences and Johnson & Johnson have amended their co-development agreement for the experimental insomnia drug MIN-202.